-The Hindu     The State population stands at a little over three crore, but average consumption of drugs is three times the national average In Kerala, where people have a marked preference for branded drugs, where the most expensive brand is considered the best, and only those brands pushed by doctors sell, the new Drug (Prices Control) Order, which is expected to cut prices by 20-25 per cent, may not have much of...

-The Indian Express Why the proposed national minimum wage is the wrong answer to questions of unemployment and poverty The recent national labour conference - a trade union love fest with little real employer participation - demanded a national minimum wage. The trade union demand is a predictable positioning of narrow self-interest as national interest but the government's acceptance of their demand is unfair, delusional and economically stupid. Unfair, because it pampers a...

-Newsclick.in A few weeks back Fortune magazine and CNN carried a long online blog titled ‘Dirty Medicine' by Dinesh Thakur, a former employ of Ranbaxy, where he recounts how he came across several procedural and other lapses in the company's manufacturing facilities. Since then the Fortune blog has become one of the most widely circulated and commented upon business stories in the world. The story received attention as it came in the...

-The Business Standard Drugs are unaffordable, but price control is the wrong answer There is little doubt that medicines in India are too expensive for most of the population. For the poorest 20 per cent of Indians, the expenditure on medicines alone is 85 per cent of what they spend on their health, according to the National Sample Survey. A World Bank study on the subject found that just out-of-pocket medical costs...

-The Economic Times MUMBAI: The United States Food and Drug Administration (USFDA), widely considered the world's most stringent regulatory authority, has said India's share in generic exports to the US over the years is an indication of the good manufacturing norms practised by Indian drugmakers. As the Ranbaxy scandal threatens to tarnish India's image as a hub of manufacturing world-class generic drugs, the statement, by USFDA's spokesman Chris Kelly in an...